Ometac 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 7.00 (6 x 4: ৳ 168.00)

Strip Price: ৳ 28.00

Medicine Details

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

20 mg once daily for 4 weeks in duodenal ulceration
8 weeks in gastric ulceration
40 mg daily in severe or recurrent cases
Prevention of duodenal ulcer relapse with 10-20 mg daily
20 mg once daily for 4 weeks in NSAID-associated duodenal or gastric ulcer
Gastro-esophageal reflux disease treatment with 20 mg once daily for 4-8 weeks
Long-term management of acid reflux disease with 10-20 mg daily
Maintenance dose for acid-related dyspepsia is 10-20 mg once daily for 2-4 weeks
Prophylaxis of acid aspiration with 40 mg on the preceding evening and 2-6 hours before surgery
Zollinger-Ellison syndrome treatment starting with 60 mg once daily, usual range 20-120 mg daily
Paediatric use in severe ulcerating reflux esophagitis with 10-40 mg once daily for 4-12 weeks

IV Injection for prophylaxis of acid aspiration with 40 mg given slowly over a period of 5 minutes
IV Infusion as an intravenous infusion over a period of 20-30 minutes or more

Reduced absorption of ketoconazole during Ometac treatment
Metabolized in the liver through cytochrome P450
Possible delay in the elimination of diazepam, phenytoin and warfarin
Increased plasma concentrations of Ometac and clarithromycin during concomitant administration
No evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin or antacids
Increased bioavailability of digoxin during simultaneous treatment with Ometac

Skin rash, urticaria and pruritus
Photosensitivity, bullous eruption, erythema multiforme, angioedema and alopecia
Diarrhoea and headache
Gastrointestinal reactions including constipation, nausea/vomiting, flatulence, and abdominal pain
Dry mouth, stomatitis and candidiasis
Paraesthesia, dizziness, and lightheadedness
Somnolence, insomnia, and vertigo
Reversible mental confusion, agitation, depression, and hallucinations
Arthritic and myalgic symptoms
Blurred vision, taste disturbance, peripheral oedema, and increased sweating
Gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, and pancytopenia
Anaphylactic shock, malaise, fever, bronchospasm, and encephalopathy
Hepatitis with or without jaundice, interstitial nephritis, and hepatic failure
Increases in liver enzymes

No adverse effects of Omeprazole on pregnancy or the fetus/newborn child from prospective epidemiological studies
Omeprazole can be used during pregnancy
No information available on the passage of Omeprazole into breast milk or its effects on the neonate
Discontinuation of breastfeeding if essential use of Omeprazole

Avoid concomitant use of clopidogrel and Ometac
Possible association of PPI therapy with an increased risk for osteoporosis-related fractures
Atrophic gastritis occasionally noted in patients treated long-term with Ometac
Concomitant use of PPIs with methotrexate may lead to methotrexate toxicities